Curaleaf-Aurora cannabis merger

What happened: U.S. cannabis firm Curaleaf has launched a hostile takeover bid for Canadian counterpart Aurora, offering $270 million. Curaleaf cited Aurora's strong international presence and medical marijuana business as key attractions. Aurora's stock has fallen significantly, and it has struggled with profitability.

Market impact: The cannabis sector is seeing a shake-up, with Curaleaf's aggressive move pushing Aurora's stock up 20% on the news. The bid could trigger further consolidation in the industry, as companies seek to expand their reach and improve profitability.

What to watch next: Aurora's board will consider the bid, with a decision expected in the coming weeks. Meanwhile, Curaleaf's earnings report, due in mid-May, will provide insight into its financial health and ability to fund the acquisition. Additionally, regulatory developments around cannabis legalization in the U.S. could impact both companies' valuations.